Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Biologic therapy.

National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Bethesda, MD
Treatments:Biologic therapyHospital:National Cancer Institute, National Institutes of Health
Drugs:Journal:Link
Date:Jan 2013

Description:

Patients:
This phase 2 study involved recurrent glioblastoma patients who were divided into two separate patient groups. Group A consisted of 32 patients with a median age of 57 years who were not previously treated with bevacizumab; 72% were male. Group B consisted of 31 patients with a median age of 54 years who were previously treated with but resistant to bevacizumab; 68% were male.

Treatment:
Patients in groups A and B were treated with the biologic therapy agent sunitinib, which is a small molecule inhibitor of VEGF receptors and interferes with cancer cell growth.

Toxicities:
Toxicity information was not separated based on patient group because both groups received the same drug and dose. There was one treatment-related death due to pneumonia in this study. Bleeding, neutropenia, and lymphopenia were also reported.

Results:
The median overall survival for groups A and B was 9.4 and 4.37 months, respectively.

Correspondence: Dr. Nguyen Kreisl; email: [email protected]



Back